314 related articles for article (PubMed ID: 34209775)
1. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
Lin YH; Lin YC; Chen CC
Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
[TBL] [Abstract][Full Text] [Related]
2. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
Liu W; Hopkins AM; Hou J
Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.
Meduri B; Pujar GV; Durai Ananda Kumar T; Akshatha HS; Sethu AK; Singh M; Kanagarla A; Mathew B
Eur J Med Chem; 2021 Oct; 222():113574. PubMed ID: 34126459
[TBL] [Abstract][Full Text] [Related]
4. Design of anticancer lysophosphatidic acid agonists and antagonists.
Parrill AL
Future Med Chem; 2014 May; 6(8):871-83. PubMed ID: 24962280
[TBL] [Abstract][Full Text] [Related]
5. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
Zhao Y; Hasse S; Zhao C; Bourgoin SG
Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic Acid Induces Ligamentum Flavum Hypertrophy Through the LPAR1/Akt Pathway.
Zhou T; Du L; Chen C; Han C; Li X; Qin A; Zhao C; Zhang K; Zhao J
Cell Physiol Biochem; 2018; 45(4):1472-1486. PubMed ID: 29466791
[TBL] [Abstract][Full Text] [Related]
7. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
Budd DC; Qian Y
Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
Llona-Minguez S; Ghassemian A; Helleday T
Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease.
Zhou Y; Little PJ; Ta HT; Xu S; Kamato D
Pharmacol Ther; 2019 Dec; 204():107404. PubMed ID: 31472182
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
12. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
Balijepalli P; Sitton CC; Meier KE
Cells; 2021 Aug; 10(8):. PubMed ID: 34440828
[TBL] [Abstract][Full Text] [Related]
14. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
Willier S; Butt E; Grunewald TG
Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
[TBL] [Abstract][Full Text] [Related]
17. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).
Parrill AL
Expert Opin Ther Pat; 2011 Feb; 21(2):281-6. PubMed ID: 21222547
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidic acid enhances human umbilical cord mesenchymal stem cell viability without differentiation via LPA receptor mediating manner.
Li N; Yan YL; Fu S; Li RJ; Zhao PF; Xu XY; Yang JP; Damirin A
Apoptosis; 2017 Oct; 22(10):1296-1309. PubMed ID: 28766061
[TBL] [Abstract][Full Text] [Related]
20. LPA receptors: subtypes and biological actions.
Choi JW; Herr DR; Noguchi K; Yung YC; Lee CW; Mutoh T; Lin ME; Teo ST; Park KE; Mosley AN; Chun J
Annu Rev Pharmacol Toxicol; 2010; 50():157-86. PubMed ID: 20055701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
